However , carnitine supplementation at dosages of ≤ 1000 mg/day ( p = 0.035 ) or equal to 2000 mg/day ( p = 0.013 ) result ed in significant reduction in ALT level , while doses more than 2000 mg/day did not change ALT  significantly .
Carnitine exerts its reducing effect on serum ALT and AST levels only when these aminotransferases are raised or when the duration of supplementation lasts at least 3 months .
Results of the current meta- analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly , especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels
Data from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease ( NAFLD ) consists of a range of complication . The disease describes clinical , para clinical and pathological conditions from simple steatosis in non-alcoholic steato hepatitis ( NASH ) to fibrosis , cirrhosis and hepato cellular carcinoma . Therefore , it is of interest to evaluate the grade of fatty liver and Liver Function Test in NAFLD patients . We collected sample s and data from 80 patients referred to gastrointestinal clinic of Emam Reza hospital with sonography diagnosed NAFLD and were evaluated in two groups in a r and omized clinical trial . The effects of L-Carnitine ( 500 mg ) prescription twice a day on liver enzymes and echogenicity changes in case group was documented and compared with the control group . The mean age of the patients was 40.7±8 in the age range of 25 to 62 years old with 66 ( 82.5 % ) male and 14 ( 17.5 % ) female patients . Data show that fatty liver changes were not significantly different in the two groups ( P=0.23 ) . It is observed that the ALT was the only enzyme with significant changes ( P=0.01 ) after a 24-week interval . It is also noted that the difference in fatty liver sonographic grading was also significant in the two groups ( P=0.0001 ) . Thus , proper therapeutic protocol s can be adopted beside diet and weight loss to control the disease trend in consideration to the significant changes observed both in enzymatic levels and sonographic grading between the two groups of patients with NAFLD
However , carnitine supplementation at dosages of ≤ 1000 mg/day ( p = 0.035 ) or equal to 2000 mg/day ( p = 0.013 ) result ed in significant reduction in ALT level , while doses more than 2000 mg/day did not change ALT  significantly .
Carnitine exerts its reducing effect on serum ALT and AST levels only when these aminotransferases are raised or when the duration of supplementation lasts at least 3 months .
Results of the current meta- analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly , especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels